文献速递艾滋病与性传播感染

终结HIV流行需要Lenacapavir强制许可

The Need for Lenacapavir Compulsory Licences in Ending the HIV Epidemic.
PubMed 文献 · Clin Infect Dis · 2025-01-01

每6个月注射一次的新型暴露前预防药物Lenacapavir高效且可能改变流行,但原研药企Gilead Sciences的HIV治疗定价超每人年4万美元,远超PrEP成本效果阈值,而规模化生产预计成本<每人年100美元。Gilead针对Lenacapavir预防和治疗的新自愿许可削弱可及性,HIV疫情快速增长的中等收入国家被排除在外,这些国家占新发HIV感染的23%。需要政府、捐赠方、民间社会和私营部门(包括Gilead)协调响应,确保Lenacapavir可及性足够广泛以消除全球HIV传播;除非对当前许可做出关键改变,否则可能需要强制许可。

要点

  • Lenacapavir作为HIV治疗定价超每人年4万美元,远超PrEP成本效果阈值。
  • 规模化生产预计成本<每人年100美元。

核心结论

  • Lenacapavir高效且可能改变HIV流行,但需确保可及性足够广泛以消除全球HIV传播;除非对当前许可做出关键改变,否则可能需要强制许可。

研究设计与样本

  • 本文为Pubmed来源的评论/观点文章,未报告系统检索范围或研究方法。

主要发现

  • Lenacapavir作为HIV治疗定价超每人年4万美元,远超PrEP成本效果阈值,即使在最富裕国家也是如此。
  • Lenacapavir规模化生产预计成本<每人年100美元。
  • Gilead针对Lenacapavir预防和治疗的新自愿许可削弱可及性,HIV疫情快速增长的中等收入国家被排除在外,这些国家占新发HIV感染的23%。

临床怎么用

  • 需要政府、捐赠方、民间社会和私营部门(包括Gilead)协调响应,确保Lenacapavir可及性足够广泛以消除全球HIV传播。
  • 除非对当前许可做出关键改变,否则可能需要强制许可。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In total, 1.3 million people acquired human immunodeficiency virus (HIV) in 2023, well behind the UNAIDS goal of <370 000 infections by 2025. Novel 6-monthly injectable pre-exposure prophylaxis (PrEP) medication lenacapavir is highly efficacious and could be epidemic-changing. However, without equitable access infection rates will continue. Gilead Sciences, the originator, currently charges over $40 000 per person-year for lenacapavir as HIV treatment, far exceeding PrEP cost-effectiveness thresholds, even in the richest countries. Yet the projected cost of production at scale is <$100 per person-year. Gilead's new voluntary license for lenacapavir prevention and treatment undermines access. Middle-income countries with fast-growing HIV epidemics have been excluded; 23% of new HIV infections occur in these countries. A coordinated response from governments, donors, civil society, and the private sector including Gilead is urgently required to ensure lenacapavir access is wide enough to eliminate HIV transmission worldwide. Unless crucial changes to the current license are made, compulsory licences may be required.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Hill A, Siedner MJ, Fairhead C, et al. The Need for Lenacapavir Compulsory Licences in Ending the HIV Epidemic. Clin Infect Dis. 2025. PMID: 40202850. doi:10.1093/cid/ciaf115

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。